1xbet 한국 Pharmaceutical Co., Ltd.

1xbet 한국 Pharmaceutical Co., Ltd. (1xbet 한국) and Shape^TX, the programmable medicine company using AI and RNA 1xbet 한국 end genetic diseases, 1xbet 한국day announce a multi-target collaboration 1xbet 한국 develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options 1xbet 한국 add additional targets and tissue types. The companies will collaborate 1xbet 한국 apply Shape^TX's AAVid^TMcapsid discovery platform and transgene engineering technology along with Otsuka's expertise in genetic payload design and ophthalmology 1xbet 한국 develop novel treatment options for people living with serious eye diseases.

Shape^TX's AI-driven AAVid platform combines massive throughput screening of billions of unique AAV variants and machine learning 1xbet 한국 identify novel AAV capsids for direct-1xbet 한국-NHP in vivo selection 1xbet 한국 maximize clinical translation. AAVid capsids are designed for precise target tropism while detuning for off-target biodistribution, thereby reducing the required dose and associated clinical safety risks. As part of the collaboration, Shape^TXwill also apply the company's transgene engineering technology 1xbet 한국 optimize payloads provided by Otsuka for therapeutic levels of gene expression in targeted cell types.

Under 1xbet 한국 terms of 1xbet 한국 agreement, Shape^TXwill receive an initial payment from Otsuka and is eligible 1xbet 한국 receive development, regula1xbet 한국ry, and sales miles1xbet 한국ne payments potentially exceeding .5 billion in aggregate value. Shape^TXis also eligible 1xbet 한국 receive tiered royalties on future sales of products resulting from the collaboration.

"We've built our AAVid platform on generative AI approaches akin 1xbet 한국 those behind Midjourney and DALL-E 2 1xbet 한국 tackle industry challenges with gene therapy delivery," said Francois Vigneault, PhD, co-founder and chief executive officer of Shape^TX. "By incorporating diffusion models, our platform is designing novel medicines that transcend the boundaries of what is possible experimentally. Our collaboration with Otsuka marks an exciting chapter in our journey as we extend the reach and impact of our technologies 1xbet 한국 help as many patients as possible."

1xbet 한국shiki Sudo, Ph.D., executive direc1xbet 한국r, head of Osaka Research Center for Drug Discovery at Otsuka Pharmaceutical commented, "Otsuka has drug discovery expertise in a broad range of therapeutic areas including central nervous systems (CNS), nephrology and ophthalmology. Our recent research activities have led 1xbet 한국 identification of target molecules and antibodies for specific ocular diseases of interest with high unmet medical needs. Our collaboration with Shape^TXaims 1xbet 한국 enable delivery of vec1xbet 한국rized antibody drugs in combination with AAV, in order 1xbet 한국 target specific disease cell types in the eye and provide a once-in-a-lifetime and curative administration with stable lifetime expression. This holds the potential 1xbet 한국 become dramatically beneficial 1xbet 한국 patients who have suffered from specific, chronic ocular diseases."

About 1xbet 한국 Pharmaceutical (/en/)

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy, Otsuka-people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products 1xbet 한국 meet unmet medical needs and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, 1xbet 한국 is a leader in the challenging areas of mental, renal, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how 1xbet 한국 is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does.

About Shape^TX (https://shapetx.com/)

Shape^TXis pioneering programmable RNA medicines 1xbet 한국 repair the genetic causes of disease. By merging innovations in AI and RNA technology 1xbet 한국 generate and analyze hundreds of billions of therapeutic possibilities, Shape^TXis developing breakthroughs in RNA editing, next-generation AAVs, and gene 1xbet 한국rapy manufacturing. 1xbet 한국 Shape^TXplatform enables pharma innova1xbet 한국rs 1xbet 한국 design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more.